Pembrolizumab plus olaparib for extensive small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This Phase 2 study tests whether combining pembrolizumab and olaparib can improve outcomes in people with extensive-stage small cell lung cancer. It mainly aims to shrink tumors and help control the cancer for longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You agree to sign the informed consent form before any study steps
- You are 18 years or older, and your cancer is confirmed as extensive-stage small cell lung cancer
- You have not had prior whole-therapy (systemic) treatment for extensive-stage small cell lung cancer
- You can provide tumor tissue for testing within 6 weeks of starting, and no cancer treatment happened between the biopsy and study start
- Your cancer has at least one measurable tumor spot on scans, and you are well enough to do daily activities (ECOG 0–1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests different treatments based on the genetic and molecular features of your tumor. It is for people with stage IV small cell lung cancer that has returned after initial chemotherapy.
This trial tests a combination of two immunotherapy drugs (ivonescimab and cadonilimab) plus chemotherapy for people with extensive-stage small cell lung cancer. It's for those who either haven't been treated before or have had only one prior treatment that included a PD-1/PD-L1 drug and it worked for a while.
This trial tests a new combination of two drugs (YL201 and serplulimab) for people with extensive-stage small cell lung cancer who have not yet received treatment. The goal is to see if the combination helps shrink or control the cancer.
This trial tests a combination of four treatments—a new immunotherapy drug, an anti-cancer medication, chemotherapy, and targeted radiation—for people with extensive-stage small cell lung cancer that cannot be removed by surgery. The goal is to see if this combination can help control the cancer and improve survival.
This trial studies how well pembrolizumab, plinabulin, and etoposide plus platinum work as first treatment for extensive-stage small cell lung cancer. It may help some people by boosting the immune response while also attacking cancer with standard chemotherapy.
This trial tests a combination of low-dose radiation, an immunotherapy drug (sugemalimab), chemotherapy, and a targeted drug (olaparib) as a first treatment for people with extensive-stage small cell lung cancer that has a specific marker called SLFN-11. The goal is to see if this combination is safe and works better than standard treatment.
Hear when a new SCLC,Extensive Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.